Search

Search Results for "Faricimab"

Faricimab in Phase 2 and 3

ARVO 2021 Coverage: TENAYA/LUCERNE Results—and Is Fluid OK in Wet AMD?

AAO Late Breaker: Ang-2 Mediation in DME Therapy

The Art of Drug Choice: Wet AMD Pipeline

Diabetic Eye Disease: What's Next for Your Patients?

ASRS 2021: ARCHWAY and TENAYA/LUCERNE

The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to Watch

Diabetic Eye Disease: What's Next for Your Patients?

Rishi Singh, MD; and Nathan Steinle, MD

Thumbnail for hyric

STAIRWAY: Faricimab for Wet AMD

Philip Ferrone

Faricimab in the Real World: 2 Years of Data thumbnail

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Faricimab in Underrepresented Patients With DME thumbnail

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

Faricimab in Wet AMD After 2 Years thumbnail

Faricimab in Wet AMD After 2 Years

Arshad M. Khanani, MD, MA

Switch Case: Faricimab to High-dose Aflibercept thumbnail

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

More on Faricimab for DME: Efficacy and Safety thumbnail

More on Faricimab for DME: Efficacy and Safety

Chirag Jhaveri, MD

Efficacy of Faricimab with PEDs Revealed thumbnail

Efficacy of Faricimab with PEDs Revealed

Jennifer I. Lim, MD

Phase 3 Faricimab Data and the Dawn of a New Molecule thumbnail

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Data Update: Faricimab for AMD & DME thumbnail

Data Update: Faricimab for AMD & DME

Carl D. Regillo, MD

View More